Therapeutic Efficacy Evaluation of Pegylated Liposome Encapsulated With Vinorelbine Plus
Animals
Antineoplastic Agents, Phytogenic
/ pharmacokinetics
Apoptosis
Cell Proliferation
Chemoradiotherapy
/ methods
Colorectal Neoplasms
/ diagnostic imaging
Humans
Indium Radioisotopes
/ pharmacokinetics
Liposomes
/ administration & dosage
Male
Mice
Mice, Inbred NOD
Mice, SCID
Multimodal Imaging
/ methods
Polyethylene Glycols
/ chemistry
Positron-Emission Tomography
Tissue Distribution
Tumor Cells, Cultured
Vinorelbine
/ pharmacokinetics
Whole Body Imaging
Xenograft Model Antitumor Assays
Biodistribution
PEG-liposome
bioluminescence
colorectal cancer
micro positron emission tomography
pharmacokinetics
Journal
Cancer genomics & proteomics
ISSN: 1790-6245
Titre abrégé: Cancer Genomics Proteomics
Pays: Greece
ID NLM: 101188791
Informations de publication
Date de publication:
Historique:
received:
30
09
2019
revised:
04
11
2019
accepted:
05
11
2019
entrez:
29
12
2019
pubmed:
29
12
2019
medline:
3
6
2020
Statut:
ppublish
Résumé
In precision therapy, liposomal encapsulated chemotherapeutic drugs have been developed to treat cancers by achieving higher drug accumulation in the tumor compared to normal tissues/organs. We developed a novel chemoradiotherapeutic approach via nanoliposomes conjugated with vinorelbine (VNB) and Pharmacokinetic results showed that the area under the curve (AUC) of PEGylated liposomes was about 17-fold higher than that of the free radioisotope. Tumor growth inhibition by The tumors in NOD/SCID mice bearing HT-29/tk-luc xenografts were significantly suppressed by
Sections du résumé
BACKGROUND/AIM
OBJECTIVE
In precision therapy, liposomal encapsulated chemotherapeutic drugs have been developed to treat cancers by achieving higher drug accumulation in the tumor compared to normal tissues/organs.
MATERIALS AND METHODS
METHODS
We developed a novel chemoradiotherapeutic approach via nanoliposomes conjugated with vinorelbine (VNB) and
RESULTS
RESULTS
Pharmacokinetic results showed that the area under the curve (AUC) of PEGylated liposomes was about 17-fold higher than that of the free radioisotope. Tumor growth inhibition by
CONCLUSION
CONCLUSIONS
The tumors in NOD/SCID mice bearing HT-29/tk-luc xenografts were significantly suppressed by
Identifiants
pubmed: 31882552
pii: 17/1/61
doi: 10.21873/cgp.20168
pmc: PMC6937124
doi:
Substances chimiques
Antineoplastic Agents, Phytogenic
0
Indium Radioisotopes
0
Liposomes
0
Polyethylene Glycols
3WJQ0SDW1A
Indium-111
E9NGC49E0T
Vinorelbine
Q6C979R91Y
Types de publication
Evaluation Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
61-76Informations de copyright
Copyright© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.
Références
CA Cancer J Clin. 2016 Jul;66(4):271-89
pubmed: 27253694
J Nucl Med. 2009 May;50(5):757-64
pubmed: 19372484
J Nucl Med. 2016 May;57(5):759-64
pubmed: 26912441
Adv Drug Deliv Rev. 2011 Mar 18;63(3):161-9
pubmed: 20869415
Biotechnol Appl Biochem. 2007 Apr;46(Pt 4):179-84
pubmed: 17073822
Recent Pat Drug Deliv Formul. 2016;10(3):177-183
pubmed: 27712569
Mol Pharmacol. 2001 Jul;60(1):225-32
pubmed: 11408618
Exp Dermatol. 2018 Feb;27(2):199-201
pubmed: 29197132
Cancer Nanotechnol. 2016;7(1):11
pubmed: 28066513
Artif Cells Nanomed Biotechnol. 2017 Feb;45(1):18-23
pubmed: 27196810
J Nucl Med. 1995 Sep;36(9):1639-44
pubmed: 7658225
J Control Release. 2000 Mar 1;65(1-2):271-84
pubmed: 10699287
Future Oncol. 2016 Feb;12(3):373-87
pubmed: 26584409
Lasers Med Sci. 2018 Feb;33(2):227-232
pubmed: 29306975
J Nucl Med. 2001 Mar;42(3):499-504
pubmed: 11337529
Int J Cancer. 2014 Aug 15;135(4):956-67
pubmed: 24470385
J Nucl Med. 2000 Sep;41(9):1519-21
pubmed: 10994732
Nucl Med Biol. 2008 Jul;35(5):623-34
pubmed: 18589307
Clin Cancer Res. 2007 May 1;13(9):2795-803
pubmed: 17473213
Int J Cancer. 1992 Jul 30;51(6):942-8
pubmed: 1639542
CA Cancer J Clin. 2015 Jan-Feb;65(1):30-54
pubmed: 25581023
Menopause. 2019 Jul;26(7):771-780
pubmed: 30649085
Drug Deliv. 2016 Nov;23(9):3319-3329
pubmed: 27145899
Proc Natl Acad Sci U S A. 1991 Dec 15;88(24):11460-4
pubmed: 1763060
Int J Nanomedicine. 2012;7:683-92
pubmed: 22359447
Cell Death Discov. 2018 Oct 31;4:100
pubmed: 30393570
J Nucl Med. 2014 Jan;55(1):115-20
pubmed: 24337605
Bio Protoc. 2018 Apr 20;8(8):null
pubmed: 29963584
Oncology (Williston Park). 2017 May 15;31(5):381-9
pubmed: 28516436
Int J Mol Sci. 2017 May 18;18(5):null
pubmed: 28524076
IUBMB Life. 2009 Jan;61(1):6-17
pubmed: 18949818
CA Cancer J Clin. 2002 Jan-Feb;52(1):23-47
pubmed: 11814064
Biochim Biophys Acta. 1992 Aug 14;1113(2):171-99
pubmed: 1510996
Int J Pharm. 2008 Jul 9;359(1-2):234-40
pubmed: 18448289
J Nucl Med. 2019 Aug;60(8):1103-1110
pubmed: 30655327
Nucl Med Biol. 2007 May;34(4):415-23
pubmed: 17499731
Int J Cancer. 1999 Mar 1;80(5):723-30
pubmed: 10048974
Int J Pharm. 2016 Jul 25;509(1-2):178-187
pubmed: 27234700
Breast Cancer Res Treat. 2007 May;102(3):375-81
pubmed: 17028979
Eur J Nucl Med Mol Imaging. 2016 May;43(5):941-952
pubmed: 26646780
Methods Mol Biol. 2016;1393:105-11
pubmed: 27033220
CA Cancer J Clin. 2015 Mar;65(2):87-108
pubmed: 25651787
Anticancer Res. 2009 Jun;29(6):2111-20
pubmed: 19528471
Semin Oncol. 1989 Apr;16(2 Suppl 4):2-4
pubmed: 2540531
Theranostics. 2017 Jan 1;7(2):319-328
pubmed: 28042337
J Nucl Med. 2009 Dec;50(12):2073-81
pubmed: 19949027
Adv Drug Deliv Rev. 2013 Jan;65(1):36-48
pubmed: 23036225
Nucl Med Biol. 2015 Mar;42(3):299-304
pubmed: 25533763